Nachman Norwood & Parrott’s AtriCure ATRC Stock Holding History

Nachman Norwood & Parrott’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-160	Closed	-$6K	–	323
2020 Q3	$6K	Buy	+160	New	+$6.79K	﹤0.01%	886

Other funds holding ATRC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Nachman Norwood & Parrott's ATRC Position: Q4 2020 in Review

Nachman Norwood & Parrott sold out of AtriCure (ATRC) in Q4 2020, closing a stake of 160 shares — an estimated $6K sold.

Nachman Norwood & Parrott first reported a position in ATRC in Q3 2020 and held it in 1 quarter. The position peaked at $6K in Q3 2020. 198 funds tracked by Wall St. Rank hold ATRC as of Q4 2020.

Nachman Norwood & Parrott reported no remaining AtriCure position as of Q4 2020 after selling out during the quarter.
Nachman Norwood & Parrott sold 160 AtriCure shares in Q4 2020, an estimated $6K.
Nachman Norwood & Parrott first reported a position in AtriCure in Q3 2020 and held it in 1 quarter.
Nachman Norwood & Parrott's AtriCure position peaked at $6K in Q3 2020.
198 funds tracked by Wall St. Rank held AtriCure as of Q4 2020.

Based on Nachman Norwood & Parrott's 13F filing for Q4 2020, filed 19 Jan 2021.